Schedule 13G ownership disclosure
LARIMAR THERAPEUTICS INC
Common Stock · CUSIP: 517125100
Event date: 2025-04-09
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Opaleye Management, Inc.
Shares: 3,952,409.00 · Class: 6.17%
- Opaleye, L.P.
Shares: 3,952,409.00 · Class: 6.17%
- James Silverman
Shares: 3,952,409.00 · Class: 6.17%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001641172-25-005093
- Form type
- SCHEDULE 13G
- Filer
- Larimar Therapeutics, Inc.
- CIK
- CIK 1374690
- Filed
- Apr 16, 2025
- Reporting period
- Apr 09, 2025
- Description
- Schedule 13G beneficial ownership